ASCO 2015 Highlights

HOPA Highlights: What's New in 2025?
HOPA Highlights
Conference Correspondent
Value-Based Cancer Care is pleased to share with you that we are on site at the 21st Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, April 9-12, 2025, in Portland, OR and together with our sister publication, the Journal of Hematology Oncology Pharmacy,we are bringing you live coverage and abstracts from the meeting.
Read Article
Disparities Noted in Treatment and Outcomes for Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Breast Cancer
Web Exclusives
n the US cohort, Black patients with HR-positive/HER2-negative mBC who underwent NGS testing were more likely to receive first-line chemotherapy, less likely to have PIK3CA mutations, and less likely to receive first-line CDK4/6 inhibitors compared with White patients.
Read Article
Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
Leukemia
Web Exclusives
round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.
Read Article
Importance of Hospital Partnerships for Bispecific Agent Implementation
Multiple Myeloma Education
Importance of Hospital Partnerships for Bispecific Agent Implementation
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma
Videos
In this ninth and final installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Lisa Raff, PharmD, MSPharm, BCPS, BCOP, discuss why hospital partnerships are critical to the successful implementation of bispecific agents into regular multiple myeloma treatment practice.
Read Article
EHR Implementation of Bispecific Agents for Multiple Myeloma
Multiple Myeloma Education
EHR Implementation of Bispecific Agents for Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma, Bispecific Antibodies
Videos
In this eighth installment, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for preparing a healthcare center’s electronic health record to accommodate bispecific agents in multiple myeloma treatment.
Read Article
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Multiple Myeloma Education
Total Cost of Care for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
In this seventh installment, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, discuss total cost of care associated with bispecific agents and other multiple myeloma treatments, as well as how that compares to the outcomes being produced.
Read Article
Study: Driving Distance From VA Hospital Influenced Cancer Care
Oncology, Multiple Myeloma
Web Exclusives
The researchers noted variations in time to treatment initiation and choice of therapy across the 3 healthcare settings, with factors such as distance from the hospital and income levels playing significant roles in delays of treatment.
Read Article
Clinical Pathways in Multiple Myeloma
Multiple Myeloma Education
Clinical Pathways in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos

In this sixth installment, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, discuss the importance of clinical pathways in multiple myeloma treatment as well as their development.

Read Article
Payer Policy Development for Bispecific Agents in Multiple Myeloma
Multiple Myeloma Education
Payer Policy Development for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos

In this fifth installment, Laura R. Bobolts, PharmD, BCOP, and Lisa Raff, MSPharm, BCPS, BCOP, discuss payer considerations when considering reimbursement and formulary inclusion of bispecific agents, as well as how payers keep up-to-date on the evolving landscape of multiple myeloma learning opportunities from bispecific therapy REMS programs.

Read Article
REMS Operational Considerations
Multiple Myeloma Education
REMS Operational Considerations
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos

In this fourth installment, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss operational considerations and potential learning opportunities from bispecific therapy REMS programs.

Read Article

Page 3 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.